EB Treatment

The Full Story

We've had the privilege of working with patients diagnosed with Dystrophic Epidermolysis Bullosa (DEB), an uncommon blistering skin ailment. Our participation in a phase 3 clinical trial marked a milestone as we contributed data to the first-ever FDA approved topical gene therapy for this condition, now commercially known as Vyjuvek. Witnessing the remarkable success of B-VEC firsthand has been truly inspiring. Over the past 3 years, we've collaborated closely with a group of DEB patients and are now thrilled to extend this treatment opportunity to a wider audience. Our skilled providers will assess your candidacy for this transformative treatment, ensuring the best possible outcome for you.

Let’s Work Together

Get in touch so we can start working together.